An interim analysis of the monarchE trial of abemaciclib plus endocrine therapy to assess overall survival as well as invasive disease–free survival and distant relapse–free survival with additional follow-up in patients with hormone receptor (HR)-positive, HER2-negative, node-positive, high-risk early breast cancer was published in The Lancet Oncology and presented at the 2022 San Antonio Breast Cancer Symposium (Abstract GS1-09).
